Back to mobile site

Mizuho on Palvella Therapeutics (PVLA): remain bullish given QTORIN potential

April 1, 2026 10:04 AM EDT Send to a Friend
Mizuho analyst Graig Suvannavejh reiterated an Outperform rating and $250.00 price target on Palvella Therapeutics (NASDAQ: PVLA)The analyst commented, "Yesterday ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login